Below you will find information from the register publication of inside information. The information has been provided by the organisation.
- Registration date 15 oct 2015 - 07:30
- Statutory name Galapagos N.V.
- Title Galapagos advances triple combination therapy in cystic fibrosis
- Comments - GLPG2665, a next-generation (C2) corrector, together with the other two components of the triple combination, show up to six-fold greater chloride transport than Orkambi1) in vitro - Triple combination therapy of C2 with GLPG2222 and GLPG1837 expected to address 80% of mutations in the CF population - Multiple series of C2 correctors identified, each with unique mode of action - GLPG2665 enters pre-clinical development and completes the first Galapagos-AbbVie triple combination therapy
Date last update: 18 October 2019